Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM).
Patients with multiple myeloma progressing on current therapies have limited treatment options. Pomalidomide (CC4047), an immunomodulatory drug, has significant activity in relapsed myeloma and previous studies suggest activity in lenalidomide refractory disease. To better define its efficacy in this group, we treated a cohort of lenalidomide refractory patients. Pomalidomide was given orally (2 mg) daily, continuously in 28-day cycles along with dexamethasone (40 mg) given weekly. Responses were assessed by the International Myeloma Working Group Criteria. Thirty-four patients were enrolled. The best response was very good partial response in 3 (9%), partial response (PR) in 8 (23%), best responses (MR) in 5 (15%), stable disease in 12 (35%) and progressive disease in 6 (18%), for an overall response rate of 47%. Of the 14 patients that were considered high risk, 8 (57%) had responses including 4 PR and 4 MR. The median time to response was 2 months and response duration was 9.1 months, respectively. The median overall survival was 13.9 months. Toxicity was primarily hematologic, with grade 3 or 4 toxicity seen in 18 patients (53%) consisting of anemia (12%), thrombocytopenia (9%) and neutropenia (26%). The combination of pomalidomide and dexamethasone (Pom/dex) is highly active and well tolerated in patients with lenalidomide-refractory myeloma.
Lacy
M Q
MQ
Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA. lacy.martha@mayo.edu
Hayman
S R
SR
Gertz
M A
MA
Short
K D
KD
Dispenzieri
A
A
Kumar
S
S
Greipp
P R
PR
Lust
J A
JA
Russell
S J
SJ
Dingli
D
D
Zeldenrust
S
S
Fonseca
R
R
Bergsagel
P L
PL
Roy
V
V
Mikhael
J R
JR
Stewart
A K
AK
Laumann
K
K
Allred
J B
JB
Mandrekar
S J
SJ
Rajkumar
S V
SV
Buadi
F
F
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003907:Dexamethasone / Q000008:administration & dosage*; D018450:Disease Progression; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality; D018570:Risk Assessment; D015996:Survival Rate; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives
D000970:Antineoplastic Agents; D013792:Thalidomide; D003907:Dexamethasone; C467566:pomalidomide
Br J Haematol. 2008 Jan;140(1):36-45
17995965
Leukemia. 2009 Jan;23(1):3-9
18971951
J Exp Med. 1998 Jun 1;187(11):1885-92
9607928
J Biol Chem. 2001 Jun 22;276(25):22382-7
11297551
J Immunol. 1999 Jul 1;163(1):380-6
10384139
Br J Haematol. 2003 Jan;120(1):10-7
12492571
Blood. 2002 Jun 15;99(12):4525-30
12036884
Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7552-6
8755512
Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):4082-5
7513432
J Clin Oncol. 2004 Aug 15;22(16):3269-76
15249589
Br J Haematol. 2008 Apr;141(1):41-51
18324965
Blood. 2001 Jul 1;98(1):210-6
11418482
Mayo Clin Proc. 2009 Dec;84(12):1095-110
19955246
Leukemia. 2006 Sep;20(9):1467-73
16855634
Semin Oncol. 2005 Aug;32(4 Suppl 5):S24-30
16085014